bupivacaine/ropivacaine

1
Reactions 772 - 9 Oct 1999 Bupivacaine/ropivacaine Motor blockade following epidural administration: 2 case reports Two women, aged 32 and 30 years, experienced profound and prolonged motor blockade after they received patient- controlled epidural analgesia with ropivacaine following combined spinal/epidural anaesthesia with standard-dose bupivacaine for elective caesarean section. Both patients received uncomplicated combined spinal/ epidural anaesthesia with 2.6ml of hyperbaric 0.5% bupivacaine. Surgery was uneventful in both patients and patient-controlled analgesia with 0.1% ropivacaine 3 ml/h with a 5ml bolus and 15 minute lock-out commenced in the recovery room before the spinal anaesthetic had regressed. The first patient noted no reduction in pain over the next 12 hours, and her highest pain score was recorded 6 hours postoperatively. Two hours later, she was still unable to move her legs and ankles and ropivacaine analgesia was stopped after 11 hours (total dose 137.4mg). One hour later, she was fully mobilised. The second patient experienced severe motor block 4 hours after she started ropivacaine analgesia and noted increasingly severe pain between 4 and 8 hours postoperatively. At 8 hours postoperatively, she had received a total dose of 55.6mg of ropivacaine; this agent was stopped 1 hour later. Her motor block resolved within 3–4 hours. Both patients received IV patient-controlled morphine in place of ropivacaine and no further sequelae were observed. Author comment: ‘It is not clear whether epidural ropivacaine may interact with intrathecal bupivacaine to prolong the effect of the latter on motor fibres in particular, but laboratory investigation of this hypothesis seems warranted.’ Buggy DJ, et al. Profound motor blockade with epidural ropivacaine following spinal bupivacaine. Anaesthesia 54: 895-898, Sep 1999 - England 800791789 1 Reactions 9 Oct 1999 No. 772 0114-9954/10/0772-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Upload: hadien

Post on 16-Mar-2017

213 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Bupivacaine/ropivacaine

Reactions 772 - 9 Oct 1999

Bupivacaine/ropivacaine

Motor blockade following epidural administration:2 case reports

Two women, aged 32 and 30 years, experienced profoundand prolonged motor blockade after they received patient-controlled epidural analgesia with ropivacaine followingcombined spinal/epidural anaesthesia with standard-dosebupivacaine for elective caesarean section.

Both patients received uncomplicated combined spinal/epidural anaesthesia with 2.6ml of hyperbaric 0.5%bupivacaine. Surgery was uneventful in both patients andpatient-controlled analgesia with 0.1% ropivacaine 3 ml/h witha 5ml bolus and 15 minute lock-out commenced in therecovery room before the spinal anaesthetic had regressed.

The first patient noted no reduction in pain over the next 12hours, and her highest pain score was recorded 6 hourspostoperatively. Two hours later, she was still unable to moveher legs and ankles and ropivacaine analgesia was stoppedafter 11 hours (total dose 137.4mg). One hour later, she wasfully mobilised.

The second patient experienced severe motor block 4 hoursafter she started ropivacaine analgesia and noted increasinglysevere pain between 4 and 8 hours postoperatively. At 8 hourspostoperatively, she had received a total dose of 55.6mg ofropivacaine; this agent was stopped 1 hour later. Her motorblock resolved within 3–4 hours.

Both patients received IV patient-controlled morphine inplace of ropivacaine and no further sequelae were observed.

Author comment: ‘It is not clear whether epiduralropivacaine may interact with intrathecal bupivacaine toprolong the effect of the latter on motor fibres in particular, butlaboratory investigation of this hypothesis seems warranted.’Buggy DJ, et al. Profound motor blockade with epidural ropivacaine followingspinal bupivacaine. Anaesthesia 54: 895-898, Sep 1999 - England 800791789

1

Reactions 9 Oct 1999 No. 7720114-9954/10/0772-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved